The aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6')-Ib] is the most widely 29 distributed enzyme among AAC(6')-I-producing Gram-negative pathogens and 30 confers resistance to clinically relevant aminoglycosides including amikacin. This 31 enzyme is therefore ideal to target with enzymatic inhibitors that could overcome 32 resistance to aminoglycosides. The search for inhibitors was carried out using 33 mixture-based combinatorial libraries, the scaffold ranking approach, and the 34 positional scanning strategy. A library with high inhibitory activity had pyrrolidine 35 pentamine scaffold and was selected for further analysis. This library contained 36 738,192 compounds with functionalities derived from 26 different amino acids 37 (R1, R2 and R3) and 42 different carboxylic acids (R4) in four R group 38 functionalities. The most active compounds all contained S-phenyl (R1 and R3) 39 and S-hydromethyl (R2) functionalities at three locations and differed at the R4 40 position. The compound containing 3-phenylbutyl at R4 (compound 206) was a 41 robust enzymatic inhibitor in vitro, in combination with amikacin potentiated the 42 inhibition of growth of three resistant bacteria in culture, and improved survival 43 when used as treatment of Galleria mellonella infected with aac(6')-Ib-harboring 44 Klebsiella pneumoniae and Acinetobacter baumannii strains. 45 46
Introduction 47
Drug resistance is a major clinical and public health problem. Several 48 nosocomial and community acquired pathogens have become resistant to many 49 different antibiotics, seriously complicating treatment and in some cases 50 becoming virtually untreatable [1] . While there are numerous antimicrobials in 51 development to treat drug resistant bacteria, the rate of introduction of new 52 antibiotic classes in the clinics is being outpaced by the growth in multidrug 53 resistant strains [1] . It is therefore desirable to find strategies to prolong the 54 effectiveness of existing antibiotics. Aminoglycosides are mainly used to treat 55 infections caused by Gram-negatives as well as Gram-positives in various 56 combination therapies [2] . Additionally, these antibiotics are used as treatments 57 of plague, tularemia, brucellosis, endocarditis and other infections caused by 58 streptococci and enterococci, as well as Mycobacterium tuberculosis infections 59
[2]. Aminoglycosides, in particular amikacin, are also administered to neonates 60 as soon as Gram-negative infections are suspected because of the high 61 morbidity and mortality that these infections have on this population [3] . 62
Unfortunately, as it is the case with other kinds of antibiotics, aminoglycosides 63 are losing their power due to the rise in the number of resistant strains [4, 5] . 64
Resistance to aminoglycosides can occur through several mechanisms that 65 can coexist simultaneously in the same cell [4, 5] . However, enzymatic 66 inactivation of the antibiotic molecule is the most prevalent in the clinical setting. 67
One of the most relevant aminoglycoside modifying enzymes is the 68 aminoglycoside 6'-N-acetyltransferase type Ib [AAC(6')-Ib] [2, 5, 6] . This enzyme, 69 present in a vast majority of AAC(6′ )-I-producing Gram-negative clinical isolates 70 [2, 5, 6] , confers resistance to amikacin and other important aminoglycosides. Of 71 high relevance is its ability to inactivate amikacin, a semisynthetic derivative of 72 kanamycin A that is one of the most refractory to the action of aminoglycoside 73 modifying enzymes and has been instrumental in the treatment of severe 74 multiresistant infections including life-threatening outbreaks in neonatal wards [3, 75 7, 8] . 76
Although considerable efforts are dedicated to designing new 77 aminoglycosides that can overcome existing mechanisms of resistance [4, 9] , 78 other alternatives to counter the action of aminoglycoside modifying enzymes are 79 being researched. They include the utilization of inhibitors of gene expression 80 such as antisense oligonucleotide analogs [10] [11] [12] , inhibitors of the enzymatic 81 activity like those developed to overcome β-lactamase-mediated resistance to β-82 lactams [5, [13] [14] [15] [16] [17] [18] , or metal ion inhibitors of the acetylation reaction, which most 83 probably act by protective chelation of the substrate antibiotic [19] [20] [21] [22] . However, 84 in spite of the efforts directed at designing inhibitors of aminoglycoside modifying 85 enzymes or their expression, none are in use in the clinics yet [reviewed in 4, 5] . 86
Recognizing the clinical relevance of AAC(6')-Ib, robust inhibitors of this enzyme 87 were searched screening mixture-based combinatorial libraries using the scaffold 88 ranking approach and the positional scanning strategy [23, 24] . This paper 89 describes the identification of an inhibitor of AAC(6')-Ib from a pyrrolidine 90 pentamine scaffold library. 91
Materials and Methods 92

Bacterial strains 93
A. baumannii A155 and K. pneumoniae JHCK1 are multidrug resistant clinical 94 strains that naturally harbor aac(6')-Ib [7, 10] . E. coli TOP10(pNW1) is a 95 laboratory strain obtained by transformation of E. coli TOP10 with pNW1, an F′ 96 derivative including aac(6')-Ib [25] . All four strains were used to test the ability of 97 selected compounds to reduce the levels of resistance to amikacin. E. coli 98 TOP10 harboring a recombinant clone where aac(6')-Ib was placed under the 99 control of the BAD promoter in the cloning vehicle pBAD102 to obtain a His-100
Patch-containing thioredoxin fused protein was used to purify the enzyme for 101 enzymatic assays [15] . 102 103
General methods 104
Purification of the enzyme was carried out as previously described [15] . 105
Enzymatic activity was determined monitoring the increase in OD 412 after the 106 reaction of 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) with the CoA-SH released 107 when acetyl CoA is used as donor for acetylation of the substrate aminoglycoside 108
[16]. Libraries were dissolved in dimethylformamide (DMF) and the final 109 concentration of DMF in the reaction mixtures used scaffold ranking was 9%. A 110 control reaction was carried out in the presence of 9% DMF. Individual 111 compounds were dissolved in dimethyl sulfoxide (DMSO) and the final 112 concentration of DMSO in the reaction mixtures was 18%. Degree of acetylation 113 was assessed monitoring OD 412 in a BioTek Synergy 2 plate reader. Initial 114 velocities (Vi) were calculated using the Gen 5 software, version 2.01.13. 115
Apparent inhibition through protein aggregation was discarded by carrying out 116 the reaction in the presence of Triton X-100 (0.1%) [15] . Results are averages of 117 three separate experiments. Mode of inhibition was determined using 118
Lineweaver-Burk plots and the Michaelis-Menten equation variations for the 119 different types of inhibition using GraphPad Prism 6 software as before [14] . 120
Datasets were generated performing a series of reactions in the presence of a 121 range of inhibitor concentrations with one substrate at a constant excess 122 concentration and the other at different concentrations. Inhibition of growth in the 123 presence of amikacin and the testing compounds were carried out in Mueller-124
Hinton broth containing the indicated additions in a microplate reader (BioTek 125 Synergy 5) as described before [20] . 126 127
Libraries, synthesis, and purification of small molecule compounds 128
All mixture-based libraries screened were synthesized at Torrey Pines 129
Institute for Molecular Studies using solid-phase chemistry approaches, 130 simultaneous multiple syntheses, and "libraries from libraries" approaches, as 131 previously described [24, [26] [27] [28] . The positional scanning library TPI1343 and all 132 individual compounds reported here were synthesized using a previously 133 described methodology [29] . Scheme 1 (Fig. S1 , supplemental material) shows 134 the general synthesis approach; a polyamide scaffold (Scheme 1; 2, Fig. S1 , 135 supplemental material) was synthesized on the solid support using standard Boc 136 chemistry, the amide residues were then reduced with borane (Scheme 1;3, Fig.  137 S1, supplemental material), and the compounds were then removed from the 138 solid support (Scheme 1; 4, Fig. S1 , supplemental material). The most active 139 individual compounds (Table 1) were synthesized using the conditions described 140
in Scheme 1 with each R position defined. 141 142
High-performance liquid chromatography (HPLC) purification 143
All purifications were performed on a Shimadzu Prominence preparative 144 HPLC system, consisting of LC-8A binary solvent pumps, an SCL-10A system 145 controller, a SIL-10AP auto sampler, and an FRC-10A fraction collector. A 146
Shimadzu SPD-20A UV detector set to 214 nm was used for detection. 147
Chromatographic separations were obtained using a Phenomenex Luna C18 148 preparative column (5 μm, 150 mm × 21.5 mm i.d.) with a Phenomenex C18 149 column guard (5 μm, 15 mm × 21.2 mm i.d.). Prominence prep software was 150 used to set all detection and collection parameters. The mobile phases for HPLC 151 purification were HPLC grade obtained from Sigma-Aldrich and Fisher Scientific. 152
The mobile phase consisted of a mixture of acetonitrile/ water (both with 0.1% 153 trifluoroacetic acid). The initial setting for separation was 2% acetonitrile, which 154 was held for 2 min, then the gradient was linearly increased to 20% acetonitrile 155 over 4 min. The gradient was then linearly increased to 55% acetonitrile over 36 156 min. The HPLC system was set to automatically flush and re-equilibrate the 157 column after each run for a total of four column volumes. The total flow rate was 158 set to 12 ml/min, and the total injection volume was set to 3900 μl. The fractions 159 corresponding to the desired product were then combined and lyophilized. (both with 0.1% formic acid for a pH of 2.7). The initial setting for analysis was 174 5% acetonitrile (v/v), and then linearly increased to 95% acetonitrile over 6 min. 175
The gradient was then held at 95% acetonitrile for 2 min before being linearly 176 decreased to 5% over 0.1 min and held until stop for an additional 1.9 min. The 177 total run time was equal to 12 min, and the total flow rate was 0.5 ml/min. The 178 column oven and flow cell temperature for the diode array detector was 30°C. 179
The auto sampler temperature was held at 15°C, and a 5 μl aliquot was injected 180 for analysis. 
Infection assays 215
Bacterial cells were collected by centrifugation and resuspended in 216 phosphate-buffered saline (PBS) (7.2 pH) with the additions indicated in each 217 assay. The number of cells inoculated was estimated based on the OD 600 and 218 the approximate number of bacterial cells inoculated was 5 x 10 5 (±0.5 log) in a 219 volume of 5 μl. The injections were performed using a syringe pump (New Era 220
Pump Systems, Inc., Wantagh, NY) with a 26-gauge by half-inch needle into the 221 hemocoel at the last left proleg after swabbing the zone with ethanol immediately 222 prior to injection. Ten healthy randomly selected final-instar G. mellonella larvae 223 (Grubco, Fairfield OH), weighing 250 mg to 350 mg, were used for each group (n 224 = 30) and the experiments were carried out in triplicate. If more than two deaths 225 occurred in either of the control groups, i.e., the PBS-injected group or the non-226 injected group, the entire trial was omitted. Larvae were incubated at 37°C for 227 120 h while in the dark while survival was recorded at 24-h intervals, removing 228 dead larvae at reported intervals. The Kaplan-Meier method was used to plot 229 resulting survival curves. A P value of 0.05 was considered statistically significant 230 for the log-rank test of survival curves (Prism 6.0, GraphPad Software Inc., La 231
Jolla, CA USA). 
Results 252
The "scaffold ranking" approach was applied to initiate the identification of 253 compounds that inhibit the AAC(6')-Ib enzyme using a small molecule mixture 254 based library in positional scanning format [24, 32] . The ranking was carried out 255 testing 37 samples that contain a mixture of all the compounds for a given 256 scaffold (Table S1, supplemental material). As described previously, these 257 scaffold-ranking samples can be prepared as synthetic mixtures or by pooling 258 together aliquots of each sample in a given positional scanning library [23, 29, 259 33] . 260
The strategy used for identifying individual compounds from the combinatorial 261 libraries is outlined in Fig. 1 . The screening of the scaffold ranking samples for 262 their inhibitory activity of AAC(6')-Ib was carried out at 25 μg/ml. Fig. 2 shows the 263 % inhibition of each of the 37 libraries tested. TPI1343, which has a pyrrolidine 264 pentamine scaffold, showed the highest inhibition level and was selected for 265 further studies. The general structure of the compounds in TPI1343 is shown in 266 functionalities. After the synthesis was completed, 120 different mixture samples 273 of pyrrolidine pentamine analogs were obtained and screened (Fig. 3) . 274
Forty-eight mixtures showed 70% or higher inhibitory activity (gray boxes, Fig.  275 4) and were selected for further dose-response tests at concentrations of 50, 25, 276 and 12.5 μg/ml. Based on the results of these tests, the functionalities of the 277 most active mixtures were selected for deconvolution, which resulted in 60 278 individual compounds (indicated by a bar in Fig. 5 and listed in Table S2 , 279 supplemental material). All 60 compounds were then synthesized and tested 280 individually at concentrations 5 and 1 μM to determine their inhibitory activity of 281 the AAC(6′)-Ib enzyme. Seven compounds showed the inhibition levels above 282 70% at 5 μM (206, 208-210, 226, 228, 229; see Table 1 and Table S2 , 283 supplemental material). One of them, compound 226, could not be further 284
analyzed because of possible chemical instability. The remainder were purified 285 along with the close structural analog 207, and used to determine their inhibitory 286 characteristics. Table 1 shows the half-maximal inhibitory concentration (IC 50 ) 287 values and structures of these compounds. IC 50 values rank between 2.1 μM 288 (compound 206) and 12.4 μM (compound 228). Kinetic analysis to determine the 289 mode of inhibition of all 7 compounds showed uncompetitive inhibition with 290 respect to acetyl CoA and mixed inhibition with respect to kanamycin A ( Fig. 6  291 and Fig. S2, supplemental material) . 292
The compounds showing the lowest IC 50 values (compounds 206-210) are 293 structural analogs that differ only in the R4 position. To assess these compounds' 294 ability to potentiate the activity of amikacin, checkerboard assays were performed 295 with these five compounds with E. coli TOP10(pNW1), A. baumannii A155 and K. 296 pneumoniae JHCK1. Compounds 207 and 208 showed the highest antimicrobial 297 activity in the absence of amikacin in the E. coli (with IC 50 s of 12 and 16 μM, 298 respectively) and A. baumannii (with IC 50 s of 12 μM each) strains, and did not 299
show consistent potentiation in any of three bacteria tested. Compound 209 also 300 showed antimicrobial activity in the absence of amikacin (with an IC 50 of 20 μM in 301 A155 and 8 μM in E. coli) but also showed 10-fold potentiation of the amikacin 302 IC 50 in A. baumannii A155 and 3-fold potentiation of the amikacin IC 50 in K. 303 pneumoniae JHCK1. Compounds 206 and 210 showed the best activity profile of 304 all, with IC 50 values greater than 24 μM in all strains and potentiation of 3-to 6-305 fold of the amikacin IC 50 in all strains (Table 2 and Table S3 , supplemental 306 material). 307
The three most favorable compounds from the checkerboard assay (206, 308 209, and 210) were then further assessed for their potential capability to be used 309 as therapeutic agents to treat amikacin-resistant infections using the G. 310 mellonella virulence model. This model of infection has been extensively 311 validated for the study of host-pathogen interactions as well as to assess the 312 efficacy of new antibiotic treatments against several bacterial pathogens [34] . 313
Infection with A. baumannii A155 or K. pneumoniae JHCK1 bacteria resulted in a 314 significant increase in mortality compared with larvae that were not injected with 315 the bacteria or were injected with sterile PBS, amikacin, or any of the compounds 316 ( Fig. 7A ). No significant reduction in mortality was observed when the individuals 317 were injected with bacteria plus amikacin or amikacin and compound 209 or 210 318 ( Fig. 7B and C ; LogRank test p>0.05 in all cases). Conversely, the group treated 319 with amikacin plus compound 206 experienced a significantly reduced mortality 320 rate ( Fig. 7B and C ; LogRank test p<0.05 for both strains). These results indicate 321 that compound 206 is a good lead for further optimization to identify a potent 322 inhibitor of the resistance to amikacin mediated by AAC(6')-Ib. 323 G. mellonella has been used before as model for evaluating toxicity [35] . The 324 infection assays using the G. mellonella model did not indicate that compound 325 206 was acutely toxic to the host at the concentrations used. To confirm this 326
result, compound 206 was tested using a standard cytotoxicity assay as 327 described in the Materials and Methods section. Addition of compound 206 to the 328 cells at concentrations higher than those needed to observe its inhibitory activity 329 did not result in significant toxicity (Fig. 8) . 
334
There are many mechanisms by which bacteria resist the action of aminoglycosides 335 but the most significant is that of enzymatic modification mediated by aminoglycoside 336 modifying enzymes [5] . Although there are more than hundred known enzymes, AAC(6')-337
Ib is by far the most common cause of amikacin resistance [7] . 338
A well-known approach to overcome resistance to antibiotics is the design of drugs 339 that interfere with the resistance and when administered in combination with the 340 appropriate antibiotic facilitate the treatment of otherwise resistant infections. This 341 approach has been highly successful in the case of β-lactams, and there are currently 342 several formulations composed of the antibiotic and the β-lactamase inhibitor in the 343 market [36, 37] . In the case of aminoglycoside antibiotics, there were numerous reports 344 identifying inhibitors of the expression of the aminoglycoside modifying enzyme as well 345 as traditional enzyme inhibitors and compounds that may inhibit the enzymatic 346 inactivation by protecting the antibiotic substrate molecule [37] . However, none of them 347 could yet be developed for its use in the clinics. 348
To identify small molecule compounds that are inhibitors of AAC(6')-Ib, we used 349 mixture-based combinatorial libraries, the scaffold ranking approach, and the positional 350 The analysis of the scaffold ranking sample that was apparently the most potent, the 360 pyrrolidine pentamine scaffold library consisting of 738,192 compounds with four 361 diversity positions (R1-R4), led to the identification of compound 206 (R1=S-phenyl, 362 R2=S-hydroxymethyl, R3=S-phenyl, R4=3-phenylbutyl). 363 AAC(6')-Ib acts through an ordered kinetic mechanism where acetylCoA is the first 364 substrate to bind [40] . Therefore, the uncompetitive inhibition exhibited by compound 206 365
indicates that it must bind the enzyme after acetylCoA. The mixed nature of the inhibition 366 with respect to the aminoglycoside substrate suggest that compound 206 interferes with 367 binding of the aminoglycoside and reduces the catalytic activity. 368
The screening of the scaffold ranking library (Fig. 2) , the pyrrolidine pentamine (Table S4 , supplemental material) 382 reveals that the R1 (S-phenyl), R2 (S-hydroxymethyl), and R3 (S-phenyl) is a critical 383 motif for activity within this series of compounds (206 through 210). R2 and R3 384 substitution analogs (compounds 201, 205, 216, and 220) displayed significantly reduced 385 activity as compared to compounds 206 and 210. The reduction in activity was less 386 significant with the R1 analogs (compounds 226, 230, 246, and 250) . Thus for AAC(6')-Ib 387 activity the R1 (S-phenyl), R2 (S-hydroxymethyl), and R3 (S-phenyl) has been identified 388 as the critical structural motif, with substitutions made at the R4 position being more 389 permissive. However, the antimicrobial activity in the absence and presence of AMK 390 differed between these compounds. Compounds 206 and 210 did not have substantial 391 antimicrobial activity alone, with MIC 50% and 90% >24 μM for E. coli TOP10(pNW1), A. 392 baumannii A155 and K. pneumoniae JHCK1, in contrast, compounds 207, 208 and 209. 393 Furthermore, compounds 206, 209 and 210 were the compounds that potentiated AMK 394 antimicrobial activity. In addition, compound 206 in combination with AMK was the only 395 compound that showed reduced mortality in the G. mellonella virulence model treated 396 with amikacin-resistant infections. In future studies, we will explore further the 397 importance and effect of R4 substitutions for enzyme activity as well as potentiation in 398 checkerboard assay. These studies could provide additional SAR data on AAC(6')-Ib 399 inhibitory activity and potentiation and will be part of the medicinal chemistry efforts to 400 produce a preclinical candidate for AAC(6')-Ib to treat drug resistant bacterial infections. 401
Furthermore, identification of these and other inhibitors could provide tools for the 402 analysis and better understanding of the AAC(6')-Ib enzymatic mechanisms. 403
Conclusions
405
Using mixture-based combinatorial libraries, the scaffold ranking approach, and the 406 positional scanning strategy we identified an inhibitor of the AAC(6')-Ib enzyme. 407
Inhibitors of resistance enzymes could be used for analysis of the properties of the 408 enzymes and molecular mechanisms of the reaction and, after further development and 409 enhancement of activity for clinical use to overcome resistance. 
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